UCB

Industry: Health Care seperator

Sector: Pharmaceuticals & Biotechnology

€ 57.82 <%= Resources.Global.txtDown %>

Updated 17/04/2014
ISIN: BE0003739530

Intraday

Market closed

Market is closed, opens at 08:00

	25 Mar	UCB: CONVENING NOTICE TO ATTEND THE ANNUAL GENERAL MEETING OF SHAREHOLDERS

	21 Feb	UCB : CONVENING NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

	26 Mar	UCB SA/NV - Convocation to the Annual General Shareholders' meeting

	22 Feb	UCB SA/NV - Convocation to the Extraordinary General Meeting

	23 Mar	UCB SA/NV: Convocation Annual Shareholders' Meeting

	29 Jun	New data for Vimpat® (lacosamide) showed sustained efficacy for up to 5 years and improved seizure control when added to a broad range of antiepileptic drugs

	18 Jun	Neupro® (rotigotine) significantly improved wellbeing and daily activities impaired due to limb pain associated with Restless Legs Syndrome

	17 Jun	Neupro® (rotigotine) showed significant benefit on early morning motor control, sleep and nocturnal symptoms in patients with Parkinson's disease

	16 Jun	Cimzia® (certolizumab pegol) shows sustained clinical improvements over three years and inhibition of joint progression in patients with rheumatoid arthritis

	16 Jun	Two-year Cimzia® (certolizumab pegol) data from study showed sustained improvements in household productivity and increased participation in social activities for rheumatoid arthritis patients

Insufficient flash player version